相关实验视频

Updated: Jul 7, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

一个新型模型的预后价值对于经过过动脉化学栓塞的肝细胞癌患者

Cailing Ye¹, Yaqiong Chen¹, Jiahao Chen¹

¹Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Journal of clinical laboratory analysis

|September 5, 2025

概括

使用中性粒细胞- 淋巴细胞比率,GGT,AFP和TNM阶段的新PI评分模型准确预测经过跨动脉化学栓塞 (TACE) 的肝细胞癌 (HCC) 患者的整体存活率. 这种新的评分优于现有的TNM和BCLC风险分层系统.

科学领域:

肝病学
癌症学
医学统计

背景情况:

接受过动脉化血栓化治疗的肝细胞癌 (HCC) 患者的临床结果不同.
准确的预后和风险分层对于个性化HCC治疗策略至关重要.

研究的目的:

在接受TACE的HCC患者中开发和验证全生存期 (OS) 的新预后模型.
该模型包含了改善个体预后估计的关键临床和实验室因素.

主要方法:

在接受TACE治疗的180名HCC患者的数据上使用考克斯回归分析来确定风险因素并构建预后模型.
通过将其预测精度与瘤结节转移 (TNM) 和巴塞罗那诊所肝癌 (BCLC) 阶段系统进行比较,评估了该模型的性能.

主要成果:

开发了一个新的预后指数 (PI) 评分,整合了中性粒细胞- 淋巴细胞比率 (NLR),γ- 谷氨基转酶 (GGT),α- 胎蛋白 (AFP) 和TNM阶段.
与TNM和BCLC分期系统相比,PI得分显示出较高的整体生存预测能力,ROC曲线下的面积分别较高 (分别为0. 746和0. 692).
根据PI得分分为四个不同的阶段的患者在OS率上表现出显著的统计差异 (p < 0. 001).

结论:

在接受TACE的HCC患者中,PI得分对整体生存有很好的预测价值.
这种新的预后模型超过了TNM和BCLC分期系统对这一患者队列的预测能力.
该PI得分有助于更准确的风险分层,为接受TACE的HCC患者做出个性化治疗决策.

关键词:

化学栓塞肝细胞癌瘤的分期预后情况生存分析治疗性的

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

相关概念视频

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...